Cargando…
Detection of KRAS mutations in plasma cell-free DNA of colorectal cancer patients and comparison with cancer panel data for tissue samples of the same cancers
Robust identification of genetic alterations is important for the diagnosis and subsequent treatment of tumors. Screening for genetic alterations using tumor tissue samples may lead to biased interpretations because of the heterogeneous nature of the tumor mass. Liquid biopsy has been suggested as a...
Autores principales: | Min, Suji, Shin, Sun, Chung, Yeun-Jun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korea Genome Organization
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6944046/ https://www.ncbi.nlm.nih.gov/pubmed/31896242 http://dx.doi.org/10.5808/GI.2019.17.4.e42 |
Ejemplares similares
-
KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010) -
KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
por: Phipps, A I, et al.
Publicado: (2013) -
KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer
por: Loupakis, F, et al.
Publicado: (2009) -
KRAS gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial cancer
por: Birkeland, E, et al.
Publicado: (2012) -
KRAS mutations in tumor tissue and plasma by different assays predict survival of patients with metastatic colorectal cancer
por: Xu, Jian-Ming, et al.
Publicado: (2014)